By physician referral or invitation only

Juvenile Psoriatic Arthritis Treatment Trial

This study is testing the safety and usefulness of a study medication named Risankizumab for patients 5 to < 18 years old.

Age & Gender

5 years ~ 17 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Eveline Wu
Pediatrics - Children's Research Institute

Study Type

Clinical or Medical
Interventional

Study Topics

Bones, Joints, Muscles
Child and Teen Health
Chronic Conditions
Rare Diseases

IRB Number

23-2583

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.